Evidence-Based Strategies for COPD Diagnosis, Management, and Prevention - Episode 11
GOLD 2025 Report: Dupilumab, a New Treatment in COPD
Panelists discuss how the BOREAS and NOTUS phase 3 trials demonstrated that dupilumab significantly reduced exacerbations, improved lung function, and enhanced quality of life in patients with uncontrolled chronic obstructive pulmonary disease (COPD), particularly those with elevated eosinophil counts, highlighting its potential in targeted therapy.
Video content above is prompted by the following:
- The 2025 GOLD recommendations include the addition of dupilumab as the first biologic treatment to reduce the frequency of COPD exacerbations in stable COPD.
- Discuss clinical outcomes with dupilumab in the BOREAS and NOTUS phase 3 trials.
